Document:

Exhibit

Exhibit 10.1

FIRST AMENDMENT 
TO CREDIT AGREEMENT
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is dated as of September 26, 2016 and is entered into by and among MASTERCARD INCORPORATED, a Delaware corporation (the “Company”), and the Lenders (as defined below) signatory hereto. Capitalized terms used herein without definition shall have the same meanings herein as set forth in the Credit Agreement after giving effect to this Amendment.
RECITALS
WHEREAS, the Company has entered into that Amended and Restated Credit Agreement, dated as of October 21, 2015, among the Company, the Subsidiary Borrowers from time to time parties thereto, the several banks and other financial institutions from time to time parties thereto (collectively, the “Lenders”), and Citibank, N.A. (“Citibank”), as managing administrative agent for the Lenders thereunder (the “Managing Administrative Agent”), and JPMorgan Chase Bank, N.A., as administrative agent for the Lenders thereunder (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”);
WHEREAS, the Company and the Lenders signatory hereto constituting the Required Lenders have agreed to amend certain provisions of the Credit Agreement;
NOW, THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:
		
	SECTION I.    
	AMENDMENTS TO CREDIT AGREEMENT

a.    Section 1.1 of the Credit Agreement is hereby amended by inserting the following defined terms in the appropriate alphabetical order therein:
“Bail-In Action”: the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.
“Bail-In Legislation”: with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule. 
“EEA Financial Institution”: (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent; 

1

“EEA Member Country”; any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
“EEA Resolution Authority”: any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
“EU Bail-In Legislation Schedule”: the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.   
“Write-Down and Conversion Powers”: with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.
b.    Section 1.1 of the Credit Agreement is hereby further amended by amending and restating clause (iv) of the defined term “Defaulting Lender” in its entirety by replacing it with the following:
“(iv) a Lender Insolvency Event has occurred and is continuing with respect to such Lender (provided that neither the reallocation of funding obligations provided for in Section 2.21 as a result of a Lender’s being a Defaulting Lender nor the performance by Non-Defaulting Lenders of such reallocated funding obligations will cause the relevant Defaulting Lender to become a Non-Defaulting Lender) or such Lender has become the subject of a Bail-in Action.”
c.    Section 2.21 of the Credit Agreement is hereby amended by amending and restating clause (c)(i) thereof in its entirety by replacing it with the following:
“(i) the Swing Line Exposure of such Defaulting Lender will, subject to the limitation in the first proviso below, automatically be reallocated (effective on the day such Lender becomes a Defaulting Lender) among the Non-Defaulting Lenders pro rata in accordance with their respective Commitments (without giving effect to such Defaulting Lender’s Commitment); provided that (i) the sum of the total outstanding principal amounts of each Non-Defaulting Lender’s Revolving Credit Loans and its Swing Line Exposure (including, as applicable, in its capacity as Swing Line Lender) may not in any event exceed the Commitment of such Non-Defaulting Lender as in effect at the time of such reallocation and (ii) subject to Section 9.21, neither such reallocation nor any payment by a Non-Defaulting Lender pursuant thereto will constitute a waiver or release of any claim any Borrower, the Managing Administrative Agent, any Swing Line Lender or any other Lender may have against such Defaulting Lender or cause such Defaulting Lender to be a Non-Defaulting Lender; and”

2

d.    Section 9 of the Credit Agreement is hereby amended by inserting the following provision immediately after Section 9.20 therein:
“9.21 Acknowledgement and Consent to Bail-In of EEA Financial Institutions.  Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)    the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and
(b)    the effects of any Bail-in Action on any such liability, including, if applicable:
(i)    a reduction in full or in part or cancellation of any such liability;
(ii)    a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or
(iii)    the variation of the terms of such liability  in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority.”
		
	SECTION II.    
	EFFECTIVENESS

This Amendment shall become effective as of the date hereof only upon the receipt by the Managing Administrative Agent (or its counsel) of a counterpart signature page of this Amendment duly executed by the Company and the Required Lenders (the date of such receipt being referred to herein as the “First Amendment Effective Date”).
		
	SECTION III.    
	REPRESENTATIONS AND WARRANTIES

In order to induce Lenders to enter into this Amendment and to amend the Credit Agreement in the manner provided herein, the Company represents and warrants to each Lender that the following statements are true and correct in all material respects:

3

a.    Corporate Power and Authority.  The Company has the corporate power and authority, and the legal right, to make, deliver and perform this Amendment and has taken all necessary corporate action to authorize the execution, delivery and performance of this Amendment.
b.    No Legal Bar.  The execution, delivery and performance of this Amendment by the Company will not violate any Requirement of Law or Contractual Obligation of the Company and will not result in, or require, the creation or imposition of any Lien on any of its properties or revenues pursuant to any such Requirement of Law or Contractual Obligation, except to the extent that such violation or imposition of Liens could not reasonably be expected to have a Material Adverse Effect.
c.    Governmental Consent. No consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority or any other Person is required in connection with the execution, delivery, performance, validity or enforceability of this Amendment, except for consents, authorizations, notices or filings that if not obtained or made, could not reasonably be expected to have a Material Adverse Effect.
d.    Binding Obligation. This Amendment has been duly executed and delivered on behalf of the Company. This Amendment constitutes a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.
e.    Incorporation of Representations and Warranties from Credit Agreement. The representations and warranties contained in Section 3 of the Credit Agreement (after giving effect to this Amendment) are and will be true and correct in all material respects (except that such representations and warranties that are qualified as to materiality are true and correct in all respects) on and as of the First Amendment Effective Date as if made on and as of such date, except for representations and warranties expressly stated to relate to a specific earlier date, in which case such representations and warranties were so true and correct as of such earlier date.
f.    Absence of Default.  No Default or Event of Default has occurred and is continuing or will result from the consummation of the transactions contemplated by this Amendment.
		
	SECTION IV.    
	MISCELLANEOUS

a.    Reference to and Effect on the Credit Agreement and the Other Loan Documents.
(i)        On and after the First Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to the “Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement as amended hereby.

4

(ii)        Except as specifically amended by this Amendment, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed.
(iii)        This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and shall be administered and construed pursuant to the terms of the Credit Agreement.
(iv)        The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of any Agent or Lender under, the Credit Agreement or any of the other Loan Documents.
b.    Headings.  Section and subsection headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose or be given any substantive effect.
c.    Applicable Law.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
d.    Counterparts.  This Amendment may be executed by one or more of the parties to this Amendment on any number of separate counterparts (including by facsimile or other electronic transmission), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.  A set of the copies of this Amendment signed by all the parties shall be lodged with the Company and the Managing Administrative Agent.
[Remainder of this page intentionally left blank.]

5

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.

MASTERCARD INCORPORATED

By:  /s/ Alfred Kibe
        Name: Alfred Kibe
        Title: Assistant Treasurer 

CITIBANK, N.A.

By:  /s/ Maureen Maroney
        Name: Maureen Maroney
        Title: Vice President

J.P. Morgan Chase Bank, N.A.

By:  /s/ Kortney Knight
        Name: Kortney Knight
        Title: Vice President

Bank of China, New York Branch

By:  /s/ Haifeng Xu
        Name: Haifeng Xu
        Title: Executive Vice President

DEUTSCHE BANK AG NEW YORK BRANCH

By:  /s/ Virginia Cosenza
        Name: Virginia Cosenza
        Title: Vice President

By:  /s/ Ming K. Chu
        Name: Ming K. Chu
        Title: Director

6

U.S. Bank National Association

By:  /s/ Allison Burgun
        Name: Allison Burgun
        Title: Vice President

The Bank of Tokyo-Mitsubishi UFJ, Ltd.

By:  /s/ Suzanne Ley
        Name: Suzanne Ley
        Title: Vice President

BARCLAYS BANK, PLC as Lender

By:  /s/ Daniel Packman
        Name: Daniel Packman
        Title: Director

GOLDMAN SACHS BANK USA

By:  /s/ Reg Williams
        Name: Reg Williams
        Title: Authorized Signatory

Industrial and Commercial Bank of China Limited, New York Branch

By:  /s/ Jeffery Roth
        Name: Jeffery Roth
        Title: Director

By:  /s/ Shulin Peng
        Name: Shulin Peng
        Title: Managing Director

7

LLOYDS BANK PLC

By:  /s/ Daven Popat
        Name: Daven Popat - P003
        Title: Senior Vice President

By:  /s/ Erin Walsh
        Name: Erin Walsh - W004
        Title: Assistant Vice President

Bank of America, N.A.

By:  /s/ Derek Miller
        Name: Derek Miller
        Title: Vice President

MIZUHO BANK, LTD.

By:  /s/ David Lim
        Name: David Lim
        Title: Authorized Signatory

THE ROYAL BANK OF SCOTLAND plc, as Lender

By:  /s/ Joseph A. Conte
        Name: Joseph A. Conte, CFA
        Title: Vice President

Bank of Montreal

By:  /s/ Lauren VonderHeid
        Name: Lauren VonderHeid
        Title: Vice President

Morgan Stanley Bank, N.A.

By:  /s/ Michael King
        Name: Michael King
        Title: Authorized Signatory

8

PNC Bank, National Association

By:  /s/ Robert M. Martin
        Name: Robert M. Martin
        Title: Senior Vice President

Commonwealth Bank of Australia

By:  /s/ Stephen McCarthy
        Name: Stephen McCarthy
        Title: Associate Director

Standard Chartered Bank

By:  /s/ Steven Aloupls
        Name: Steven Aloupls A2388
        Title: Managing Director

Wells Fargo Bank, N.A.

By:  /s/ Heidi Samuels
        Name: Heidi Samuels
        Title: Director

Commerzbank AG, New York Branch

By:  /s/ Pedro Bell
        Name: Pedro Bell
        Title: Director

By:  /s/ Anne Culver
        Name: Anne Culver
        Title: Assistant Vice President

HSBC Bank USA, N.A.

By:  /s/ David Rebibo
        Name: David Rebibo
        Title: Director

9

BANCO SANTANDER, N.A.

By:  /s/ Federico Robin
        Name: Federico Robin
        Title: Executive Director

By:  /s/ Paloma Garcia Castro
        Name: Paloma Garcia Castro
        Title: Associate

10EXHIBIT
10.1

 

Exact
name of Investor as it should appear on Stock Certificate:

 

OXYGEN
THERAPY, INC. 

 

SUBSCRIPTION
AGREEMENT

 

SUBSCRIPTION
AGREEMENT by and between the investor named above (the “Investor”) and Oxygen Therapy, Inc., (the “Company”)
a Delaware corporation with offices at 202 Lenox Ave, Unit #1, New York, NY 10026. This Subscription Agreement shall be deemed
to include the attached Terms and Conditions which hereby are incorporated by reference.

 

	A.	Aggregate
    Investment:	$________
	 	 	 
	 	Securities:
    	Shares
    of the Company’s Common Stock, $.001 par value per share (“Shares”), coupled with warrants for the
    purchase of Shares at an exercise price of $1.20 per share (the “Warrants”; the Warrants and Shares collectively
    are sometimes referred to as the “Securities” and a single Share coupled with a Warrant is sometimes referred
    to as a “Unit”). 
	 	 	 
	 	 	The
    purchase price per Unit is $1.00; and for the Minimum Investment of $100,000, the Company will issue 100,000 Shares and a
    Warrant to purchase $100,000 shares at an exercise price of $1.20 per Share.
	B.	Address,
    etc.:	________________________________________
	 	 	________________________________________
	 	Telephone:	________________________________________
	 	Facsimile:	________________________________________

 

	C.	Accredited
    Investor Status (initial as many as apply):

 

	 	_______	The
    Investor is a natural person whose individual net worth, or joint net worth with the Investor’s spouse, exceeds $1,000,000;
	 	 	 
	 	_______	The
    Investor is a natural person who had an individual income in excess of $200,000 in each of 2014 and 2015 or joint income with
    that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same
    income level in 2016.

 

    	 	 	 

     

    

 

	 	_______	The
    Investor is a trust of which each beneficiary has an individual or joint (together with such beneficiary’s spouse) net
    worth in excess of $1,000,000, or (b) expects to have an annual income in 2016, and represents that such beneficiary had an
    annual income in each of 2014 and 2015 in excess of $200,000 (or joint annual income in excess of $300,000).
	 	 	 
	 	_______	The
    Investor is an organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or
    similar business trust, a partnership or a limited liability company which has total assets in excess of $5,000,000 and which
    was not formed for the specific purpose of acquiring the securities offered hereby.
	 	 	 
	 	_______	For
    purposes of calculating net worth for the above representations, the value of a person’s primary residence, and the
    amount of indebtedness secured by such primary residence, up to the amount of such value shall be excluded from the calculation.
    Indebtedness secured by the residence in excess of the value of the home should be considered a liability and deducted from
    the person’s net worth.1

 

	D.	Status
    as a Non-U.S. Person (initial if applicable):

 

	 	_______	The
    Investor is not a natural person resident of the United States, partnership or corporation organized in the United States,
    or trust of which the trustee is a natural person resident of the United States (each of the foregoing, a “U.S. Person”),
    and certifies further that it is not acquiring the Securities for the account or benefit of any U.S. Person or is a U.S. Person
    who purchased securities in a transaction that did not require registration under the Act.

 

The
Investor acknowledges that he or it has received and reviewed this Agreement in its entirety, including without limitation the
representations and warranties set out in Section 3 below. The Investor and the Company each executes this Agreement as an instrument
under seal.

 

 

1 By
way of example, if a person had net assets of $1,000,000 (excluding their primary residence) and a primary residence worth $2,000,000
with a $1,000,000 mortgage, their net worth for the purposes of the above accredited investor representations would be $1,000,000
even if by other measures of net worth, the $1,000,000 net worth in the residence ($2,000,000-the $1,000,000 mortgage) would be
added to the $1,000,000 in other net assets. If the mortgage were $3,000,000 rather than $1,000,000, the person would be deemed
to have a net worth of $0. The $1,000,000 net worth from other assets would be reduced by the $1,000,000 excess liability in the
house ($2,000,000 residence value - $3,000,000 mortgage).

 

    	 	2	 

     

    

 

	Investor
    (if individual)	 
	 	 
	 	 

 

	Investor
    (if entity)	 
	 	 	 
	Print
    Name: 	 	 

 

	By:
    	 	 
	 	 	 
	Title:	 	 

 

OXYGEN
THERAPY INC.

 

SIGNATURE
PAGE

 

The
Company hereby accepts this subscription subject to the terms and conditions set forth in this Agreement as of this _______ day
of August, 2016.

 

	 	OXYGEN
    THERAPY, INC.
	 	 	 
	 	By:	 
	 	Name:	Yuval
    Kwintner
	 	Title:	President

 

    	 	3	 

     

    

 

1.Subscription.
Subject to the terms and conditions of this Agreement, the Investor irrevocably subscribes for and agrees to purchase
_________ Units. At Closing, the Company will issue to the Investor a certificate representing _________ Shares and a Warrant
for the purchase of _________ Shares exercisable at $1.20 per share. The Investor shall pay the Purchase Price for the Securities
in cash to the Company by check or wire transfer.

 

2.Acceptance
of Subscription.

 

This
Subscription is made subject to the following terms and conditions:

 

2.1.This
subscription shall be deemed accepted by the Company upon execution by the Company of this Subscription Agreement.

 

2.2.Upon
the sale by the Company to the Investor of the Securities, the Investor will receive a copy of this Subscription Agreement executed
by an officer on behalf of the Company.

 

3.Closing.
The subscription shall close upon acceptance at the sole discretion of the Company upon the receipt by the Company of Subscription
Agreements (including this Agreement) to purchase an aggregate of at least $200,000 in aggregate principal amount of the Securities
(the “Initial Closing”). The Company may sell additional Securities, at one or more additional closings (collectively,
the “Additional Closings” and collectively with the Initial Closings, the “Closings” and
each a “Closing”).

 

4.Representations
and Warranties of the Investor. The Investor understands and acknowledges that (a) the Securities are being offered and
sold under one or more of the exemptions from registration provided for in Section 4(2) or Section 3(b) of the Securities Act
of 1933, as from time to time amended (the “Securities Act”), including Regulation D promulgated thereunder and, if
the Investor is a Non-U.S. Person, Regulation S promulgated thereunder, and any applicable state securities laws, (b) he or it
is purchasing the Securities without being offered or furnished any offering literature or prospectus other than a certain power
point presentation dated August 16, 2016, copies of the Company’s charter and by-laws, a copy of the Company’s “487”
Patent and documents relating to the Company’s bridge round of financing, including forms of Convertible Note and Warrant
(collectively, the “Written Disclosure”) and (c) this transaction has not been reviewed or approved by the
United States Securities and Exchange Commission or by any regulatory authority charged with the administration of the securities
laws of any state or foreign country. The Investor also represents and warrants as follows:

 

4.1.Citizenship,
Age and Residence. He or she is at least 21 years of age, if a natural person, and is a bona fide resident and domiciliary
(not a temporary or transient resident) of the state and at the address described in Section B and has no present intention of
becoming a resident of any other State or other jurisdiction.

 

4.2.Suitability.
The Investor understands and has fully considered for purposes of this investment the risks of this investment and understands
that (i) this investment is suitable only for an investor who is able to bear the economic consequences of losing his or her entire
investment, (ii) the purchase of the Securities is a speculative investment which involves a high degree of risk of loss by the
Investor of his or her entire investment, (iii) there are substantial restrictions on the transferability of, and there will (for
the foreseeable future) be no public market for, the Securities, and accordingly, it may not be possible for an indeterminate
period of time to liquidate his or her investment in the Securities (if ever). Furthermore, the Investor represents that he or
she has sufficient liquid assets so that the lack of liquidity associated with this investment will not cause any undue financial
difficulties or affect the ability of the Investor to provide for his or her current needs and possible financial contingencies.

 

    	 	4	 

     

    

 

4.3.Investment
Information. The Investor acknowledges that the Written Disclosure contains the views of the management of the Company,
and that the analysis or presentation of the Company’s obligations and prospects, to the extent reflected therein, represents
a subjective assessment about which reasonable persons could disagree.

 

4.4.Access
to Information. The Investor, in making his, her or its decision to purchase the Securities, has relied solely upon the
Investor’s independent investigations and has, if requested, been given (i) access to all material books and records of
the Company; (ii) access to all material contracts and documents relating to the transaction described herein; and (iii) an opportunity
to ask questions of, and to receive answers from, the appropriate executive officers and other persons acting on behalf of the
Company concerning the Company and its prospects and the terms and conditions of this Offering, and to obtain any additional information,
to the extent such persons possess such information or can acquire it without unreasonable effort or expense, necessary to verify
the accuracy of the information set forth in the Written Disclosure. The Investor acknowledges that no request to the Company
by the Investor for information of any kind about the Company has been refused or denied by the Company or remains unfulfilled
as of the date of this Agreement.

 

4.5.Investment
Intent. The Securities are being acquired by the Investor solely for the Investor’s own personal account, for investment
purposes only, and not with a view to, or in connection with, any resale or distribution of the Securities or of the Shares issuable
upon exercise of the Warrants (such Shares are referred to in this Subscription Agreement as the “Other Securities”);
the Investor has no contract, undertaking, understanding, agreement or arrangement, formal or informal, with any person to sell,
transfer or pledge to any person any of the Securities or the Other Securities or any interest or rights in any of the Securities
or Other Securities; the Investor has no present plans to enter into any such obligation; and the Investor understands the legal
consequences of the representations and warranties made by him or her in this Agreement to mean that he or she must bear the economic
risk of the investment for an indefinite period of time because neither the Securities nor the Other Securities have been registered
under the Securities Act and applicable state securities laws and, therefore, cannot be sold unless they are subsequently registered
under the Securities Act and applicable state securities laws (which the Company is not obligated, and has no current intention,
to do) or unless an exemption from such registration becomes available.

 

4.6.No
Distribution of Offering Materials. The Investor has not distributed the Written Disclosure to any other person or party
other than Investor’s advisors; and he has not used the Written Disclosure for any purposes other than to evaluate the merits
of an investment in the Company.

 

    	 	5	 

     

    

 

4.7.Control
of Funds. The Investor represents that the funds provided for this investment are the separate property of the Investor
or are otherwise funds as to which the Investor has the sole right of management.

 

4.8.Review
of Written Disclosure. The Investor has carefully read the Written Disclosure. In evaluating the suitability of an investment
in the Company, the Investor has not relied upon any representations or other information (whether oral or written) other than
as set forth in the Written Disclosure or as contained in any documents or answers to questions furnished by the Company.

 

4.9.Sophistication
of Investor. The Investor either (i) has a preexisting personal or business relationship with the Company or its controlling
persons, such as would enable a reasonably prudent purchaser to be aware of the character and general business and financial circumstances
of the Company or its controlling persons, or (ii) by reason of his or her business or financial experience, individually or in
conjunction with his or her unaffiliated professional advisors, the Investor is capable of evaluating the merits and risks of
an investment in the Securities, making an informed investment decision and protecting his or her own interests.

 

4.10.Accuracy
of Information. All of the information set forth on the cover page of this Agreement, including without limitation the
Accredited Investor Status indicated as applicable to the Investor, is true and correct in all respects.

 

4.11.Contacts
with the Company. The Investor’s initial contacts with the Company were not as a result of the Company’s filing
of a registration statement on Form S-1 or on any other form for registering its shares of capital stock for sale nor was the
Investor contacted by the Company in connection with the offering of securities pursuant to such registration statement. The Investor
either has a pre-existing business relationship with the Company or has engaged in discussions with the Company regarding establishing
a business relationship.

 

4.12.No
Brokers. The Investor has not engaged any broker, dealer, finder, commission agent or other similar person in connection
with the offer, offer for sale, or sale of the Securities and is not under any obligation to pay any broker’s fee or commission
in connection with his investment.

 

4.13.Securities
Act Compliance. The Investor understands that the easiest way to sell his or her Securities or Other Securities in the
future would be to sell in an initial underwritten public offering of the Company’s securities or to a purchaser of the
entire Company or its business. In the absence of a public offering or such a sale, however, the Investor may sell his or her
Securities or Other Securities in compliance with various private sale exemptions under applicable securities laws. Accordingly,
the Investor understands that:

 

a.Neither
the Securities nor the Other Securities have been registered under the Securities Act, by reason of a specific exemption under
the provisions of the Securities Act which depends in part upon the investment intent and the representations and warranties of
the Investor made in this Agreement.

 

b.In
issuing the Securities to the Investor, the Company is relying upon these representations and warranties.

 

    	 	6	 

     

    

 

c.Any
routine sales of the Securities or Other Securities in reliance upon Rule 144 under the Securities Act (if the provisions of such
Rule should then be available as to the Securities or Other Securities) can be made only after the holding period specified in
the Rule, in limited amounts, and in accordance with all the terms and conditions of that Rule.

 

d.In
the case of securities to which Rule 144 is not applicable, compliance with Regulation A under the Securities Act or some other
exemption will be required.

 

e.Rule
144 is not now available with respect to the Securities or the Other Securities.

 

f.The
Company is under no obligation to register the Securities or the Other Securities or to comply with Regulation A or any other
exemption under the Securities Act or to supply any information necessary to permit routine sales under Rule 144.

 

g.The
Company may, if it so desires permit the transfer of the Securities or the Other Securities and of all securities issued in exchange
therefore only when such Securities or Other Securities are the subject of an effective registration statement under the Securities
Act or when the Company has received an opinion of counsel that such registration is not required under the Securities Act. The
Investor agrees to furnish such documentation and undertakings as the Company and its counsel may reasonably require in connection
with any such opinion, whether under Rule 144 or some specific exemption under the Act.

 

h.The
Company may place certain legends on the Securities or the certificate(s) for the Other Securities as required by applicable laws,
including a legend in form substantially as follows and, with respect to Securities or Other Securities issued to Investors who
are not U.S. Persons a legend referencing transfer restrictions applicable to the Securities or Other Securities issued pursuant
to Regulation S:

 

[This
Warrant] [The securities represented by this certificate] have not been registered under the Securities Act of 1933, as amended
(the “Act”), or applicable state securities laws and none of such securities, nor any interest therein, may be sold,
transferred, assigned, made the subject of any security interest, or otherwise disposed of, without an effective registration
statement for such securities under the Act and applicable state securities laws, or an opinion of counsel in form and substance
satisfactory to the Company that registration is not required under the Act or such state securities laws.

 

i.If
the Investor is not a U.S. Person, the Investor shall only resell the Shares of the Other Securities in accordance with the provisions
of Regulation S promulgated under the Act, pursuant to registration under the Act, or pursuant to an available exemption from
registration.

 

    	 	7	 

     

    

 

5.Representations
and Warranties of the Company.

 

The
Company hereby represents and warrants to the Investor:

 

5.1.Organization,
Qualifications and Corporate Power.

 

a.The
Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware, and
is duly licensed or qualified to transact business as a foreign corporation and is in good standing in each other jurisdiction
in which the nature of the business transacted by it or the character of the properties owned or leased by it requires such licensing
or qualification. The Company has the full corporate power and authority and possesses all governmental franchises, licenses,
permits, authorizations and approvals necessary to enable it to own or lease and hold its properties and to carry on its business
as now conducted and as proposed to be conducted, to execute, deliver and perform this Agreement, and other transaction documents
contemplated hereby and thereby, and to issue, sell and deliver the Securities and the Other Securities.

 

b.The
Company does not (i) own of record or beneficially, directly or indirectly, (A) any shares of capital stock or securities convertible
into capital stock or other equity interest of any other corporation or (B) any participating or other equity interest in any
partnership, joint venture or other non-corporate business enterprise or (ii) control, directly or indirectly, any other entity.

 

5.2.Authorization
of Agreements, Etc.

 

a.The
execution and delivery by the Company of this Agreement and related transaction documents, the performance by the Company of its
obligations hereunder and thereunder, and the issuance, sale and delivery of the Securities and the Other Securities have been
duly authorized by all requisite corporate action and will not violate any provision of law, ordinance, rule or regulation applicable
to the Company or its property or business, or any order, judgment or decree of any court or other agency, administrative body
or other governmental body, the Articles of Incorporation of the Company, as amended (the “Charter”) or the By-laws
of the Company, as amended, or any provision of any indenture, agreement or other instrument to which the Company or any of its
properties or assets is bound, or conflict with, result in a breach of or constitute (with due notice or lapse of time or both)
a default under any such indenture, agreement or other instrument, or result in the creation or imposition of any lien, charge,
restriction, claim or encumbrance of any nature whatsoever upon any of the properties or assets of the Company.

 

b.The
Securities and the Other Securities have been duly authorized and, when issued in accordance with this Agreement, the Conversion
Shares will be validly issued, fully paid and non-assessable shares of the capital stock, of the Company, with no personal liability
attaching to the ownership thereof, and will be free and clear of all liens, charges, restrictions, claims and encumbrances of
any kind.

 

5.3.Validity.
This Subscription Agreement and the related transaction documents have been duly executed and delivered by the Company
and constitute the valid and binding obligations of the Company, enforceable against the Company in accordance with their respective
terms.

 

    	 	8	 

     

    

 

5.4.Authorized
Capital Stock. The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock, par value $0.001
per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. Other than: (a) 22,250,000 shares of common stock
currently outstanding and held beneficially and of record by the founders of the Company and (b) shares of capital stock issuable
upon conversion of outstanding Convertible Notes and the exercise of outstanding warrants, and (c) Shares issuable upon exercise
of Warrants issued to the Investor and other Investors investing in the Company on the same terms, (i) no person owns of record
or is known to the Company to own beneficially any share of the Company’s capital stock, (ii) no subscription, warrant,
option, convertible security, or other right (contingent or other) to purchase or otherwise acquire equity securities of the Company
is authorized or outstanding, (iii) there is no commitment by the Company to issue shares, subscriptions, warrants, options, convertible
securities, or other such rights or to distribute to holders of any of its equity securities or any evidence of indebtedness or
asset.

 

5.5.Litigation;
Compliance with Law.

 

a.There
is no (i) action, suit, claim, proceeding or investigation pending or, to the best of the Company’s knowledge, threatened
against or affecting the Company or any of its properties or assets, at law or in equity, or before or by any Federal, state,
municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, (ii) arbitration
proceeding relating to the Company pending under collective bargaining agreements or otherwise, or (iii) governmental inquiry
pending or, to the best of the Company’s knowledge, threatened against or affecting the Company (including without limitation
any inquiry as to the qualification of the Company to hold or receive any license or permit), and there is no basis for any of
the foregoing. The Company has not received any opinion or memorandum or legal advice from legal counsel to the effect that it
is exposed, from a legal standpoint, to any liability or disadvantage which may be material to its business, prospects, financial
condition, operations, property or affairs. The Company is not in default with respect to any order, writ, injunction or decree
known to or served upon the Company of any court or of any Federal, state, municipal or other governmental department, commission,
board, bureau, agency or instrumentality, domestic or foreign. There is no action or suit by the Company pending or threatened
against others. The Company has complied with all laws, rules, regulations and orders applicable to its business, operations,
properties, assets, products and services, the Company has all necessary permits, licenses and other authorizations required to
conduct its business as conducted and as proposed to be conducted, and the Company has been operating its business pursuant to
and in compliance with the terms of all such permits, licenses and other authorizations. There is no existing law, rule, regulation
or order, and the Company after due inquiry is not aware of any proposed law, rule, regulation or order, whether Federal, state,
county or local, which would prohibit or restrict the Company from, or otherwise materially adversely affect the Company in, conducting
its business in any jurisdiction in which it is now conducting business or in which it proposes to conduct business.

 

5.6.Proprietary
Information of Third Parties. No third party has claimed or has reason to claim that the Company or any person employed
by or affiliated with the Company has (a) violated or may be violating any of the terms or conditions of his employment, non-competition
or nondisclosure agreement with such third party, (b) disclosed or may be disclosing or utilized or may be utilizing any trade
secret or proprietary information or documentation of such third party, or (c) interfered or may be interfering in the employment
relationship between such third party and any of its present or former employees. No third party has requested information from
the Company which suggests that such a claim might be contemplated. To the best of the Company’s knowledge, no person employed
by or affiliated with the Company has employed or proposes to employ any trade secret or any information or documentation proprietary
to any former employer, and no person employed by or affiliated with the Company has violated any confidential relationship which
such person may have had with any third party in connection with the development, manufacture or sale of any product or proposed
product or the development or sale of any service or proposed service of the Company, and the Company has no reason to believe
there will be any such employment or violation.

 

    	 	9	 

     

    

 

5.7.Title
to Properties. The Company has good, clear and marketable title to its properties and assets, and all such properties
and assets (including the Intellectual Property) are free and clear of mortgages, pledges, security interests, liens, charges,
claims, restrictions and other encumbrances (including without limitation, easements and licenses), except for liens for or current
taxes not yet due and payable and minor imperfections of title, if any, not material in nature or amount and not materially detracting
from the value or impairing the use of the property subject thereto or impairing the operations or proposed operations of the
Company and its subsidiaries, including without limitation, the ability of the Company to secure financing using such properties
and assets as collateral.

 

5.8.Other
Agreements. The Company is not a party to or otherwise bound by any written or oral contract or instrument or other restriction
with any of the shareholders of the Company which affects the capitalization or ownership of the Company.

 

5.9.Assumptions,
Guaranties, Etc. of Indebtedness of Other Persons. The Company has not assumed, guaranteed, endorsed or otherwise become
directly or contingently liable on any indebtedness of any other person (including, without limitation, liability by way of agreement,
contingent or otherwise, to purchase, to provide funds for payment, to supply funds to or otherwise invest in any person).

 

5.10.Governmental
Approvals. Subject to the accuracy of the representations and warranties of the Investor set forth in Section 4, no registration
or filing with, or consent or approval of or other action by, any Federal, state or other governmental agency or instrumentality
is or will be necessary for the valid execution, delivery and performance by the Company of this Agreement, or the related transaction
documents or the issuance, sale and delivery of the Securities or the Other Securities.

 

5.11.Offering
of the Securities. Neither the Company nor any person authorized or employed by the Company as agent, broker, dealer or
otherwise in connection with the offering or sale of the Securities or any security of the Company similar to the Securities has
offered the Securities or any such similar security for sale to, or solicited any offer to buy the Securities or any such similar
security from, or otherwise approached or negotiated with respect thereto with, any person or persons, and neither the Company
nor any person acting on its behalf has taken or will take any other action (including, without limitation, any offer, issuance
or sale of any security of the Company under circumstances which might require the integration of such security with Securities
under the Securities Act or the rules and regulations of the Commission thereunder), in either case so as to subject the offering,
issuance or sale of the Securities to the registration provisions of the Securities Act.

 

    	 	10	 

     

    

 

6.Miscellaneous.

 

6.1.Notices.
All notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered
or first class mail, postage prepaid or express overnight courier service, to the address set forth on the cover page hereof.

 

6.2.Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of The Commonwealth of Massachusetts,
excluding its conflicts of laws rules.

 

6.3.Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof
and may be amended or superseded only by a writing executed by the parties.

 

7.Continuing
Effect of Representations, Warranties and Acknowledgments. The Investor and the Company agree that the representations
and warranties of Section 4 and Section 5, respectively, are true and accurate as of the date of this Subscription Agreement and
shall be true and accurate as of the date of delivery to and acceptance by the Company of this Subscription Agreement, and shall
survive such delivery and acceptance. If in any respect such representations, warranties and acknowledgements shall not be true
and accurate prior to such delivery and acceptance, the Investor or the Company, as the case may be, shall give immediate written
notice of such fact to the Company or the Investor, specifying which representations and warranties and acknowledgements are not
true and accurate and the reasons therefore.

 

8.Indemnification.
The Investor understands the meaning and legal consequences of Investor’s representations and warranties contained
in Section 4, and agrees to indemnify and hold harmless the Company, its officers or any of its directors, affiliates, controlling
shareholders, counsel, agents, or employees from and against any and all loss, damage or liability (including costs and reasonable
attorneys’ fees due to or arising out of a breach of any representation, warranty or acknowledgment of the Investor contained
in this Agreement; and the Company understands the meaning and legal consequences of its representations and warranties contained
in Section 5 of this Agreement and in the other documents and agreements executed by the Company as contemplated by the transactions
described in this Agreement, and agrees to indemnify and hold harmless the Investor, its officers or any of its directors, affiliates,
controlling shareholders, counsel, agents or employees from and against any and all loss, damage or liability (including costs
and reasonable attorneys’ fees) due to or arising out of a breach of any representation, warranty or acknowledgment of the
Company contained herein or therein.

 

    	 	11	 

     

    

 

	Investor
    (if individual)	 
	 	 
	 	 
	Print
    Name: 	 
	 	 
	Investor
    (if entity)	 

 

	Print
    Name:	 	 

 

	By:
    	 	 
	 	 	 
	Title:	 	 

 

PAYMENT
INSTRUCTIONS: 

 

Please
submit this signed agreement with payment. Investor may send funds in the form of check, money order or bank wire. Wiring instructions
are as follows:

 

PAYMENT
BY BANK WIRE TO:

 

Please
make reference to “Oxygen Therapy, Inc.” 

 

	Bank
    Name:	Bank
    of America
	 	 
	Escrow
    Account Name:	Oxygen
    Therapy Inc.
	 	 
	Account
    Number:	0046
    6564 6591
	 	 
	ABA
    Wire Payment Number:	026009593
	 	 
	Swift
    Code:	BOFAUS3N
	 	 
	Branch
    Addresses:	Bank
    of America
	 	235
    Needham St. 
	 	Newton
    MA, 02464

 

    	 	12	 

     

    

 

PAYMENT
BY CHECK OR MONEY ORDER:

 

Investor
will send check or money order payable to Oxygen Therapy, Inc. to the following address:

 

	Oxygen
    Therapy, Inc.	 
	 	 
	 	 
	 	 

 

Investor
may contact the Company directly at (617)-510 2539 or by email: david.platt@otipharma.com

 

The
contact person is David Platt.

 

    	 	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]